Other Clinical Trial - Orelabrutinib Combined With Pemetrexed For

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04516655` - A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients	Phase 2
Recruiting	`NCT05054426` - Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL	Phase 3
Recruiting	`NCT02623010` - Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma	Phase 2
Recruiting	`NCT04548648` - A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas	Phase 2
Active, not recruiting	`NCT00293475` - Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Phase 1/Phase 2
Completed	`NCT03342586` - Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
Terminated	`NCT02420795` - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05625594` - Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma	Phase 1
Completed	`NCT01011920` - Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma	Phase 2
Completed	`NCT00967200` - Study of Tissue Samples From Patients With Glioma or Other Brain Tumors	N/A
Recruiting	`NCT03684980` - LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma	Early Phase 1
Recruiting	`NCT04938297` - Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma	Phase 2
Completed	`NCT01458730` - Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma	Phase 2
Completed	`NCT00153530` - Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)	Phase 4
Active, not recruiting	`NCT03962127` - MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Completed	`NCT03690895` - Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
Recruiting	`NCT05114330` - Secondary Central Nervous System Lymphoma Registry - Charité
Completed	`NCT00103038` - Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases	N/A
Recruiting	`NCT03964090` - Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)	Phase 2
Recruiting	`NCT02952508` - Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia	Phase 2

NCT number	NCT05209620
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Zhihua Yao, M.D. Ph.D
Phone	+8613592622292
Email	zlyyyaozhihua1260@zzu.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	December 21, 2021
Completion date	December 21, 2026

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms